Adam Feuerstein of STAT tweeted: “The success of $XLRN luspatercept is bad for $GERN and another reason for $JNJ to sever the imetelstat relationship in Q3.” In early trading, Acceleron Pharma (XLRN) shares are up $13.76, or 40%, to $47.74 while Geron (GERN) shares are fractionally lower.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.